Daewoong Pharmaceutical said Wednesday that the company signed a contract with AZothBio to research and develop synthetic lethality anticancer treatments using artificial intelligence on Sept. 16.AZothBio is a new drug-developing AI platform company. The company’s AI-based new drug developing platfo
"Global pharmaceutical companies are constantly finding new ways to develop innovative drugs despite the recent Covid-19 pandemic."Yoshitake Maeda, the director of Bristol Myers Squibb (BMS)'s business development, search and evaluation for Japan and Asia, explained so during the Seoul International
Celltrion said Wednesday that it obtained a domestic license from the Ministry of Food and Drug Safety (MFDS) for its Avastin biosimilar, Vegzelma (ingredient name: bevacizumab).Consequently, Vegzelma will be able to sell all indications for the drug such as metastatic direct bowel cancer, non-small
Huons Biopharma said it has won product approval for Hutox, its botulinum toxin (BTX) product, in Ecuador.The approval follows the company’s exclusive supply deal with Saludderma, an Ecuador-based aesthetic firm, in May 2020.With the approval, Saludderma plans to launch Hutox in the country by the e
Ildong Pharmaceutical has requested for changing its previous application for oral Covid-19 treatment candidate substance, Xocova (S-217622).In a public notice Tuesday, Ildong said it had applied to the Ministry of Food and Drug Safety to approve the change in phase 2/3 clinical trial of an investig
"It is quite possible to globalize Korean medicines and medical supplies.”CEO Huh Kyung-hwa of the Korea Innovative Medicines Consortium (KIMCo) affirmed so during a meeting with reporters to commemorate the second anniversary of the consortium’s establishment.KIMCo is a non-profit foundation set up
HLB Therapeutics said that it submitted a clinical protocol to the U.S. FDA on Monday to conduct a second phase 3 clinical trial for a neurotrophic keratitis (NK) treatment through its U.S. subsidiary, ReGenTree.NK is a degenerative disease in which the sensation of the cornea gradually decreases, a
Korean biopharmaceutical companies are turning to rights offering from investors and institutions to raise insufficient funds.A rights offer can help companies raise secondary capital by issuing rights to the company's existing shareholders to buy additional shares in proportion to their existing sh
Boryung said it received product approval from the Ministry of Food and Drug Safety for Zepzelca (Ingredient: lurbinectedin), a small cell lung cancer (SCLC) drug licensed-in from PharmaMar, a Spanish-based pharmaceutical company, in 2017.Under the approval, hospitals can use the drug in treating pa
HK inno.N said it would develop an ointment with a JAK inhibitor mechanism to treat atopic dermatitis (AD).At an investor relations meeting on Wednesday, the Kosdaq-listed firm unveiled the status of major pipelines. In particular, the company introduced a new drug candidate IN-A002 in the JAK-1 inh
The Korea Exchange (KRX) will review and decide on whether to delist Kolon Tissugene, SillaJen, and Qurient in October, as the three companies have submitted all the details of the implementation of improvement plans. The three companies had received a grace period from the KRX to improve their busi
PARP inhibitors, which had emerged as the most common targeted therapy for unresectable ovarian cancer, could increase death risk in patients who experienced several chemotherapies, a recent study showed, forcing developers to withdraw their indications.AstraZeneca reportedly distributed an official
MSD Korea said on Friday that Keytruda (ingredient: pembrolizumab) obtained domestic approval as a combination therapy with chemotherapy, with or without bevacizumab, as the primary treatment for patients with persistent, recurrent or metastatic cervical cancer.Consequently, Keytruda has now been ap
HanAll Biopharma and Yuyu Pharmaceutical are accelerating efforts to develop dry eye treatments, witnessing a global increase in the prevalence of the disease, also known as xerophthalmia.According to a study published in the Ophthalmic and Physiological Optics, a research journal of optometrists, t
It is becoming increasingly important for individual researchers or research institutes to conduct research after proposing research topics. This is because the results of the study are reflected in clinical treatment guidelines or incentivize the development of new drugs and medical devices. In the
Spectrum Pharmaceuticals, Hanmi Pharmaceutical’s U.S. partner, said the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted nine to four against poziotinib, a lung cancer drug candidate, saying benefits of the drug did not outweigh risks.Poziotinib aims to treat
Dupixent (dupilumab), the first approved biological drug for treating atopic dermatitis, has not just improved symptoms in oral corticosteroid-dependent asthma patients but demonstrated the effect of reducing steroid use.Sanofi said so, releasing its three-year, long-term data on severe asthma patie
The Korean market for ginkgo leaf extracts that improve blood circulation disorders and cognitive impairment is growing rapidly.According to UBIST, a drug market research firm, domestic sales of Ginkgo biloba extract preparations grew from 40.4 billion won ($28.6 million) in 2017 to 56.6 billion won
Janssen’s Imbruvica (ibrutinib) and BeiGene’s Brukinsa (zanubrutinib), the two BTK (bruton tyrosine kinase) inhibitors with the same mechanism, received two different review results from the Health Insurance Review and Assessment Service’s (HIRA) cancer drug reimbursement review committee.The review
Celltrion is drawing the industry’s attention by setting about to develop a new drug based on a bispecific antibody to treat HER2-positive breast cancer.Celltrion said Wednesday that it signed a contract with Abpro Corp., a U.S. bio company, to co-develop ABP102, a bispecific treatment candidate tar